The FDA approved the oral factor D inhibitor danicopan (Voydeya) as an add-on therapy to treat extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria (PNH), AstraZeneca announced.

The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...

Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...

The first-in-class oral factor D inhibitor danicopan (Voydeya) has been approved for the management of extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). EVH affects ...

Published Apr 1, 2024 7:00am EDT Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial WILMINGTON, Del. -- (BUSINESS WIRE)-- VOYDEYA™ (danicopan) has ...

The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...

Hemotransfusion in treatment of anemia, 3D illustration showing two populations of red blood cells, small hypochromic red blood cells and normal. A small lymphocyte is drawn for size comparison ...

ASH 2025 highlighted many investigational agents for paroxysmal nocturnal hemoglobinuria (PNH) that may not reach clinical practice soon, notes Dr Jamile M. Shammo, though bispecific antibodies show ...

CLEVELAND, Dec. 12, 2022 /PRNewswire/ -- NovelMed Therapeutics is a clinical-stage biotechnology company focused on developing anti-complement therapies for rare (orphan) diseases. NovelMed announced ...